| Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) (NCT03016130) | University of Florida | 2017-08-18 |
| Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors (NCT03238248) | Vanderbilt-Ingram Cancer Center | 2017-08-07 |
| Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS) (NCT02929498) | GlaxoSmithKline | 2017-07-31 |
| Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly (NCT02867085) | Technische Universität Dresden | 2017-07-19 |
| Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (NCT03066648) | Novartis Pharmaceuticals | 2017-07-06 |
| A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT03164057) | St. Jude Children's Research Hospital | 2017-06-15 |
| Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) (NCT03140280) | Ehab L Atallah | 2017-06-05 |
| Safety and Activity of Digoxin With Decitabine in Adult AML and MDS (NCT03113071) | Fox Chase Cancer Center | 2017-06-02 |
| Clinical and Laboratory Parameters of Myelodysplastic Syndromes at Upper Egypt (NCT06244173) | Sohag University | 2017-06-01 |
| A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes (NCT03151304) | Helsinn Healthcare SA | 2017-06-01 |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) (NCT02564536) | Washington University School of Medicine | 2017-06-01 |
| Nivolumab With Chemotherapy in Refractory MDS (NCT03259516) | St. Petersburg State Pavlov Medical University | 2017-05-25 |
| Clinical and Genomic Registry of MDS in Asia (NCT03169296) | The University of Hong Kong | 2017-05-08 |
| B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) (NCT02493829) | King's College London | 2017-05-01 |
| Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes (NCT03121014) | University of Illinois at Chicago | 2017-04-24 |
| CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia (NCT02995655) | Washington University School of Medicine | 2017-04-07 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation (NCT02981914) | University of Chicago | 2017-03-07 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment (NCT03011034) | Janssen Research & Development, LLC | 2017-02-14 |
| Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT (NCT03018223) | H. Lee Moffitt Cancer Center and Research Institute | 2017-01-31 |
| Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs (NCT02907359) | Astex Pharmaceuticals, Inc. | 2017-01-13 |
| Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics (NCT03027401) | National Cancer Institute (NCI) | 2017-01-10 |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study (NCT03733249) | Bellicum Pharmaceuticals | 2017-01-01 |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery (NCT02955043) | University of Wisconsin, Madison | 2016-12-22 |
| Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy (NCT02856464) | King's College Hospital NHS Trust | 2016-12-21 |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies (NCT02743351) | Fate Therapeutics | 2016-12-20 |
| Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT) (NCT04602273) | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | 2016-12-12 |
| King's Invasive Aspergillosis Study II (NCT02875743) | King's College Hospital NHS Trust | 2016-12-07 |
| Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent (NCT03045510) | Shandong University | 2016-12-01 |
| A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) (NCT03030612) | OncoVerity, Inc. | 2016-12-01 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773) | University of Arizona | 2016-11-29 |
| A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes (NCT02848001) | Celgene | 2016-11-14 |
| Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS (NCT02969980) | Asan Medical Center | 2016-11-01 |
| A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes (NCT02841540) | Hemavant Sciences GmbH | 2016-10-06 |
| CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT (NCT02942173) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2016-10-01 |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG (NCT02916979) | Dartmouth-Hitchcock Medical Center | 2016-09-06 |
| Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome (NCT02909972) | Aileron Therapeutics, Inc. | 2016-09-01 |
| A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS) (NCT02835794) | University of Florida | 2016-08-01 |
| Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia (NCT03083054) | University of Campinas, Brazil | 2016-08-01 |
| A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms (NCT02842229) | Celgene | 2016-07-20 |
| Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant (NCT02477878) | Bellicum Pharmaceuticals | 2016-07-01 |
| Investigation of the Genetics of Hematologic Diseases (NCT02720679) | St. Jude Children's Research Hospital | 2016-06-17 |
| Development of an in Vitro Hematopoietic Culture System and Application to Myelodysplastic Syndromes. (NCT03107273) | Centre Hospitalier Universitaire, Amiens | 2016-06-16 |
| An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) (NCT02775903) | Celgene | 2016-06-03 |
| Tipifarnib in Subjects With Myelodysplastic Syndromes (NCT02779777) | Kura Oncology, Inc. | 2016-06-01 |
| A Study of Pevonedistat in Adult East Asian Participants (NCT02782468) | Millennium Pharmaceuticals, Inc. | 2016-05-16 |
| Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease (NCT02370888) | University of Florida | 2016-05-16 |
| Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT (NCT02786485) | Bellicum Pharmaceuticals | 2016-05-01 |
| Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes (NCT02721875) | Boehringer Ingelheim | 2016-04-28 |
| PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. (NCT02689622) | University Hospital, Toulouse | 2016-04-20 |
| An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) (NCT02610777) | Millennium Pharmaceuticals, Inc. | 2016-04-14 |
| Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (NCT03659084) | Hospices Civils de Lyon | 2016-04-01 |
| Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS) (NCT02781441) | Institut Paoli-Calmettes | 2016-04-01 |
| Prophylactic Application of Donor-derived TCM After Allogeneic HSCT (NCT02758223) | Wuerzburg University Hospital | 2016-04-01 |
| A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) (NCT02641002) | Celgene | 2016-03-01 |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (NCT02631070) | Celgene | 2016-02-09 |
| Institut Paoli Calmettes Myelodysplastic Syndromes Database (NCT03275480) | Institut Paoli-Calmettes | 2016-01-18 |
| Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (NCT02598661) | Geron Corporation | 2016-01-12 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (NCT02593123) | Virginia Commonwealth University | 2015-11-04 |
| A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (NCT02498665) | Sumitomo Pharma America, Inc. | 2015-11-01 |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children (NCT02646839) | Michael Pulsipher | 2015-10-01 |
| Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (NCT02576301) | Mateon Therapeutics | 2015-10-01 |
| A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes (NCT02508870) | Hoffmann-La Roche | 2015-09-30 |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (NCT02356159) | National Cancer Institute (NCI) | 2015-09-24 |
| Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine (NCT02489929) | Assistance Publique Hopitaux De Marseille | 2015-08-01 |
| Identification of Molecular Defects in Idiopathic Cytopenia of Undetermined Significance (NCT02804984) | Centre Hospitalier Universitaire, Amiens | 2015-07-09 |
| Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes (NCT02281084) | Celgene | 2015-07-06 |
| Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT (NCT02627573) | St. Petersburg State Pavlov Medical University | 2015-07-01 |
| iCare for Cancer Patients (NCT02435550) | University of Florida | 2015-06-26 |
| Umbilical Cord Blood Transplantation From Unrelated Donors (NCT03016806) | University of Rochester | 2015-06-01 |
| Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia (NCT02335268) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2015-05-21 |
| Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q (NCT02928419) | Associazione Qol-one | 2015-05-01 |
| Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT (NCT02472691) | Heinrich-Heine University, Duesseldorf | 2015-05-01 |
| Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (NCT02452983) | Gustavo Rivero | 2015-05-01 |
| Study of TCP-ATRA for Adult Patients With AML and MDS (NCT02273102) | University of Miami | 2015-03-02 |
| Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR (NCT02497404) | Weill Medical College of Cornell University | 2015-02-13 |
| Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes (NCT02240706) | Boehringer Ingelheim | 2015-01-22 |
| A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome (NCT02328950) | Fujian Medical University | 2014-12-01 |
| A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT02308761) | Hoffmann-La Roche | 2014-11-06 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS (NCT02488408) | BerGenBio ASA | 2014-10-22 |
| Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003) (NCT02268383) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2014-10-09 |
| Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors (NCT02211755) | National Cancer Institute (NCI) | 2014-10-06 |
| Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT (NCT02294552) | Ivan S Moiseev | 2014-10-01 |
| A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) (NCT02243124) | Eleos, Inc. | 2014-09-01 |
| Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes (NCT02228525) | Memorial Sloan Kettering Cancer Center | 2014-08-27 |
| A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS) (NCT02145026) | Hoffmann-La Roche | 2014-08-06 |
| Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT02201329) | Boehringer Ingelheim | 2014-08-01 |
| Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome (NCT02269592) | Dana-Farber Cancer Institute | 2014-08-01 |
| Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes (NCT02619097) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2014-06-01 |
| Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (NCT02117115) | Washington University School of Medicine | 2014-06-01 |
| Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 (NCT02320656) | Institut Paoli-Calmettes | 2014-05-01 |
| Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant (NCT03301168) | Bellicum Pharmaceuticals | 2014-04-01 |
| Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS) (NCT02038816) | Sunnybrook Health Sciences Centre | 2014-03-01 |
| A Study of Galunisertib in Participants With Myelodysplastic Syndromes (NCT02008318) | Eli Lilly and Company | 2014-03-01 |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation (NCT02074839) | Institut de Recherches Internationales Servier | 2014-03-01 |
| Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia (NCT03408210) | Affiliated Hospital to Academy of Military Medical Sciences | 2014-03-01 |
| Connect® Myeloid Disease Registry (NCT01688011) | Celgene | 2013-12-12 |
| Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes (NCT01913951) | Washington University School of Medicine | 2013-11-22 |